What Has Been The Evolution of the Antibody Drug Conjugates Contract Manufacturing Market in Recent Years?
The antibody drug conjugates contract manufacturing market has seen considerable growth due to a variety of factors.
• In recent years, there has been notable escalation in the size of the antibody drug conjugates contract manufacturing market. The market, which is worth $9.57 billion in 2024, is anticipated to reach $10.55 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.2%.
This growth during the historic period is engendered by factors such as the growing prevalence of cancer, increased demand for targeted treatments, advancements in antibody drug conjugates, heightened levels of investment in research and development, approval of new ADCs by the regulatory bodies, and the expansion activities undertaken by pharmaceutical corporations.
What Are the Future Growth Projections for the Antibody Drug Conjugates Contract Manufacturing Market?
The antibody drug conjugates contract manufacturing market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size of antibody drug conjugates contract manufacturing is predicted to experience robust growth, surging to $15.37 billion in 2029 with a compound annual growth rate (CAGR) of 9.9%.
The anticipated elevation during the projection period could be due to the expected expansion of personalized medicine, broadening utilisation beyond oncology, escalating partnerships among biotech and pharma firms, increased use of ADCs in clinical studies, and a heightened focus on affordable manufacturing solutions. Key trends in the forecast period encompass progress in biomarker identification, advancements in biotechnology, an increased embrace of next-generation ADC technologies, enhancement in linker and payload technologies, and the incorporation of artificial intelligence into drug development.
What Are the Critical Driver Fuelling The Antibody Drug Conjugates Contract Manufacturing Market's Growth?
The expansion of the biopharmaceutical industry is predicted to accelerate the growth of the antibody-drug conjugates contract manufacturing market. This industry focuses on the creation, production, and marketing of drugs created from biological sources, using biotechnology and molecular biology to generate novel therapies and treatments. The rapid growth of the biopharmaceutical industry is largely due to advancements in biotechnology, the increasing need for personalized medicine, and heightened investment in research and development for innovative cures and therapies. The biopharmaceutical industry relies on contract manufacturing of antibody-drug conjugates (ADCs) to provide specialized production services which aid in the development and marketing of these therapies. These companies are able to ramp up production efficiently and maintain superior quality standards while focusing on their primary research and development areas. For example, in May 2024, the Department of Health and Social Care reported that the UK's core biopharmaceutical sector contributed £46.7 billion ($59.32 billion) to the country's revenue in 2021/22, a significant 43% of the entire life sciences industry. Thus, the blossoming biopharmaceutical industry fuels the growth of the antibody-drug conjugates contract manufacturing market.
What Are The Major Segments Within The Global Antibody Drug Conjugates Contract Manufacturing Market?
The antibody drug conjugates contract manufacturingmarket covered in this report is segmented –
1) By Type: Immunoglobulin G1(Igg1), Immunoglobulin G4(Igg4)
2) By Linker: Cleavable Linker, Non-Cleavable Linker
3) By Condition: Myeloma, Lymphoma, Breast Cancer, Other Conditions
4) By Phase: Clinical, Commercial
Pre-Book The Antibody Drug Conjugates Contract Manufacturing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Antibody Drug Conjugates Contract Manufacturing Market?
Key players in the antibody-drug conjugates contract manufacturing marketplace are concentrating their efforts on creating innovative solutions like single-use reactors. These are designed to bolster production flexibility, minimize the likelihood of contamination, and streamline the manufacturing process, ultimately amplifying the efficiency and scalability of ADC production. The evolution of the field of antibody-drug conjugates contract manufacturing can be attributed to the single-use reactors, which offer an efficient, flexible, and contamination-free method for producing these intricate biologics. For instance, in September 2024, the US-based life science firm MilliporeSigma, introduced the Mobius ADC Reactor, a single-use reactor. The Mobius ADC Reactor is explicitly engineered to manufacture antibody-drug conjugates efficiently. The reactor incorporates cutting-edge mixing and control technologies that simplify conjugation, enhance scalability, and ensure consistent results. This groundbreaking reactor supports increased yields and superior quality control in the ADC production, catering to the escalating demand for targeted cancer treatments with advanced safety and efficiency.
Who Are the Key Players In The Antibody Drug Conjugates Contract Manufacturing Market?
Major companies operating in the antibody drug conjugates contract manufacturing market are:
• AbbVie Inc.
• Eli Lilly and Company
• Gilead Sciences Inc.
• Merck KGaA
• Boehringer Ingelheim
• Recipharm AB
• Sigma-Aldrich
• Sartorius AG
• Curia
• Lonza Group AG
• Catalent Inc.
• KBI Biopharma
• Alcami Corporation
• Formosa Laboratories
• BioVectra Inc.
• Axplora
• Abzena PLC
• ImmunoGen Inc.
• EirGenix Inc.
• Avid Bioservices Inc.
• Mersana Therapeutics
• Cerbios-Pharma SA
• Creative Biolabs
• Aurigene Pharmaceutical Services Ltd.
• Sterling Pharma Solutions
What Is The Most Dominant Region In The Antibody Drug Conjugates Contract Manufacturing Market?
North America was the largest region in the antibody drug conjugates contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody drug conjugates contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
